Trk C Monoclonal Antibody BT-MCA1233
Specifications
| 50ul / 100ul |
Background:
This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation and may play a role in the development of proprioceptive neurons that sense body position. Mutations in this gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers. Several transcript variants encoding different isoforms have been found for this gene.
Classification:
Primary antibody
Alternative names:
NTRK3; TRKC; NT-3 growth factor receptor; GP145-TrkC; Trk-C; Neurotrophic tyrosine kinase receptor type 3; TrkC tyrosine kinase
Species reactivity:
Human
Host:
Mouse
Isotype:
IgG
Immunogen:
Purified recombinant extracellular fragment of human Trk C (aa32-429) fused with hIgGFc tag expressed in HEK293 cells.
Concentration:
1 mg/ml
Molecular weight:
N/A
Applications:
WB, IHC-p, IF, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.